Literature DB >> 579434

Experience of antioxidant treatment in neuronal ceroid-lipofuscinosis of Spielmeyer-Sjögren type.

P Santavuori, R Moren.   

Abstract

A therapeutic trial with antioxidants in neuronal ceroid lipofuscinosis (NCL) of Spielmeyer-Sjögren type is presented. The series consisted of 46 patients, 23 of whom received antioxidants while 23 served as controls. At the start of the trial the patients were classified into two groups on the basis of their IQs. Eleven children, aged 6 1/2 to 12 years, were of low normal or subnormal intelligence (treatment group I). After an observation period of 5 to 6 years a significant change in IQ was seen in 6 children; an improvement was noticed in 2 boys and a deterioration in 4 patients. The IQs were higher, the neurological signs less marked and epilepsy less frequent among the patients receiving antioxidants than among the controls. The therapy did not benefit vision and it was unsuccessful in advanced cases. The results are discussed and compared with those reported by other authors.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 579434     DOI: 10.1055/s-0028-1091529

Source DB:  PubMed          Journal:  Neuropadiatrie        ISSN: 0028-3797


  3 in total

1.  Clinical trials in rare disease: challenges and opportunities.

Authors:  Erika F Augustine; Heather R Adams; Jonathan W Mink
Journal:  J Child Neurol       Date:  2013-09       Impact factor: 1.987

2.  Short-Term Administration of Mycophenolate Is Well-Tolerated in CLN3 Disease (Juvenile Neuronal Ceroid Lipofuscinosis).

Authors:  Erika F Augustine; Christopher A Beck; Heather R Adams; Sara Defendorf; Amy Vierhile; Derek Timm; Jill M Weimer; Jonathan W Mink; Frederick J Marshall
Journal:  JIMD Rep       Date:  2018-06-20

3.  Juvenile Batten's disease: an ophthalmological assessment of 26 patients.

Authors:  D J Spalton; D S Taylor; M D Sanders
Journal:  Br J Ophthalmol       Date:  1980-10       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.